Anhedonia is a major depressive disorder that results in an inability to gain pleasure from normally enjoyable experiences. It is a core symptom in depression and is also frequently seen in people suffering with bipolar depression, schizophrenia, substance-abuse disorders, Parkinson’s disease, diabetes, and coronary artery disease. The habenula circuit in the epithalamus moderates dopamine, serotonin, and other neurotransmitter pathways. Its role in reward processing is well established, indicating a potential therapeutic pathway target for anhedonia. G Protein-Coupled Receptor 139 (GPR139) is an orphan receptor in the habenula and a potential target for anhedonia therapeutic development.

NBI-1065846: An Investigational Therapy for Anhedonia in Depression

NBI-1065846 (TAK041) is a potential first-in-class, investigational GPR139 agonist for the treatment of anhedonia in depression.

Clinical Trials: Anhedonia in Depression

Neurocrine Biosciences plans to initiate a Phase 2 study of NBI-1065846 in patients with anhedonia in depression in 2021.